Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia

Status: Recruiting
DFCI Protocol ID:

The purpose of this study is to assess safety and amount of the study drug in the blood after increasing doses of SP-420. The study will be conducted in patients with β-thalassemia.

Conducting Institutions:

Children's Hospital Boston, Dana-Farber Cancer Institute

Overall PI:

Ellis Neufeld, MD, PhD, Brigham and Women's Hospital

Site-responsible Investigators:


Dana-Farber Cancer Institute: Childrens Hospital Pediatric Clinical Translation Investigation Program CTIP,

Eligibility Criteria

Inclusion Criteria:

  -  Subject has iron-overload secondary to β-thalassemia requiring chronic red blood cell
     transfusions and iron chelation therapy

  -  Subject weighs ≥35 kg

  -  Subject is willing to discontinue current iron chelation therapy at least 7 days
     prior to the first dose of SP-420 and for the duration of the study

  -  Serum ferritin ≥700 ng/mL and iron saturation ≥70% within 3 weeks before Baseline
     (Day 1)

  -  Cardiac T2* score >20 msec within 6 months before Baseline (Day 1)

  -  Willing to use contraception during the study

Exclusion Criteria:

  -  Pregnant or breast-feeding

  -  Serum creatinine greater than the upper limit of normal

  -  Platelet count <100 × 10^9/L

  -  Use of another investigational drug within the last 30 days

  -  Significant cardiac, renal, hepatic dysfunction or other clinically significant
     conditions that, in the opinion of the Investigator, would exclude the subject

Know Your Options

Not sure which clinical trials might be right for your child? Email our clinical trials team at
We can help you navigate your options.

Get Clinical Trial Updates


Stay informed about Dana-Farber/Boston Children's research efforts, including information on new and current clinical trials. Sign up to receive our email newsletter Advances in Pediatric Hematology/Oncology.

Download Our Clinical Trials

Download a list of our open clinical trials. Check back regularly for updates.